Artelo Biosciences, Inc. (ARTL, Financial) experienced a significant stock price increase of 5%, reaching $1.16 per share. The trading volume was 68,784 shares with a turnover rate of 2.13% and a volatility of 9.55%. Recent financial reports show zero revenue, a net loss of $1.13 million, and an EPS of -$0.35. Despite this, all three rating agencies recommend buying the stock. The biotechnology sector saw a modest increase of 0.12%, with notable activity in Protara Therapeutics, Inc. and Molecular Templates, Inc.
Artelo Biosciences is a U.S.-based biopharmaceutical company focusing on therapies targeting lipid signaling pathways, including the endocannabinoid system. It aims to develop cannabinoid-based treatments for rare diseases.
